Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | BAD | Q92934 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764416 | 0.76 | TDP1 (0.38) | RAB9ANPC1SMN1; SMN2POLBNOTUM | |
| SCHEMBL3516703 | 0.76 | CYP1A2 (0.39) | RAB9ANPC1SMN1; SMN2POLBNOTUM | |
| SCHEMBL9465377 | 0.67 | LPL (0.33) | ALDH1A1HSD17B10KDM4ELMNAHPGD | |
| SCHEMBL1854697 | 0.67 | ALDH1A1 (0.36) | RAB9ANPC1SMN1; SMN2NOTUMALDH1A1 | |
| SCHEMBL9465257 | 0.67 | CYP2A6 (0.41) | TDO2 | |
| SCHEMBL12562793 | 0.66 | BCL2L1 (0.55) | RAB9ANPC1SMN1; SMN2POLBNOTUM | |
| SCHEMBL10300262 | 0.66 | BCL2L1 (0.55) | RAB9ANPC1SMN1; SMN2POLBNOTUM | |
| SCHEMBL10337645 | 0.66 | BCL2L1 (0.55) | RAB9ANPC1SMN1; SMN2POLBNOTUM | |
| SCHEMBL197346 | 0.66 | BCL2L1 (0.55) | RAB9ANPC1SMN1; SMN2POLBNOTUM | |
| SCHEMBL1435891 | 0.66 | CYP2A6 (0.54) | SMN1; SMN2ALDH1A1TP53HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836188-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006070198-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | claimed |
| CN-105732581-A | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS IV | ABBVIE 公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-102933548-B | Carboxamide compounds and their use as calpain inhibitors | ABBOTT LAB | 2015-03-11 | — | — | CN | disclosed |
| CN-103443094-A | Pyrazole derivative | TAISHO PHARMACEUTICAL CO LTD | 2013-12-11 | — | — | CN | disclosed |
| CN-102933548-A | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO KG | 2013-02-13 | — | — | CN | disclosed |
| CN-102753541-A | Carboxamide compounds and their use as calpain inhibitors iv | ABBOTT GMBH & CO KG | 2012-10-24 | — | — | CN | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1836188-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006070198-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | RAB9A 3141/4885NPC1 3024/4885SMN1; SMN2 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.